Stay updated on Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial

Sign up to get notified when there's something new on the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The website has been updated to version v2.10.0, adding 8 more conditions and 2 more interventions/treatments, while removing the previous version v2.9.7.
    Difference
    0.5%
    Check dated 2024-07-23T14:20:45.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T06:23:42.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the version of the content on the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T12:16:17.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T09:03:16.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Last Update Posted (Estimated) Revision has been updated from v2.9.1 to v2.9.3, indicating a revision in the information provided on the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T08:13:36.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value of the web page has recently changed to show updated information about a phase II trial evaluating the efficacy of autologous tumor infiltrating lymphocytes MDA-TIL in treating patients with recurrent or refractory ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma. The study aims to assess various outcomes such as objective response rate, disease control rate, duration of response, progression-free survival, overall survival, and safety profile of the treatment.
    Difference
    41%
    Check dated 2024-06-25T07:58:49.000Z thumbnail image

Stay in the know with updates to Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page.